Polypid Ltd(PYPD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 6:25 PM ET (Korea 10/31 07:25)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.48 | Insider Own | 63.91% | Shs Outstand | 20.3M | Perf Week | 2.67% |
| Market Cap | 0.11B | Forward P/E | - | EPS next Y | -1112.26% | Insider Trans | - | Shs Float | 7.3M | Perf Month | 0.37% |
| Enterprise Value | 0.10B | PEG | - | EPS next Q | 0.91 | Inst Own | 17.1% | Short Float | 3.08% | Perf Quarter | 23.62% |
| Income | -0.03B | P/S | - | EPS this Y | 104.94% | Inst Trans | 5.49% | Short Ratio | 1.9 | Perf Half Y | 21.4% |
| Sales | 0.00B | P/B | 20.32 | EPS next 5Y | 41.66% | ROA | -119.05% | Short Interest | 0.23M | Perf YTD | 24.19% |
| Book/sh | 0.27 | P/C | 16.17 | EPS past 3/5Y | -0.87% 14.14% | ROE | -243.59% | 52W High | -7.71% ($5.84) | Perf Year | 40.36% |
| Cash/sh | 0.33 | P/FCF | - | Sales past 3/5Y | - | ROIC | -555.57% | 52W Low | 54% ($3.50) | Perf 3Y | 42.59% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 61.3% | Gross Margin | - | Volatility(W/M) | 5.2% 5.38% | Perf 5Y | -97.47% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.27 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.14 | EPS Q/Q | 55.37% | Profit Margin | - | RSI (14) | 54.68 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.35 | Sales Q/Q | - | SMA20 | 4.76% ($5.15) | Beta | 1.45 | Target Price | $11.4 |
| Payout | - | Debt/Eq | 0.29 | Earnings | 2026/11/11 | SMA50 | 3.86% ($5.19) | Rel Volume | 0.85 | Prev Close | $5.59 |
| Employees | 75 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | 7.28% - | SMA200 | 14.03% ($4.73) | Avg Volume(3M) | 0.12M | Price | $5.39 |
| IPO | 2020/6/26 | Option/Short | Yes/Yes | Trades | 590 | Volume | 101,561 | Change | -3.58% |
💊 PolyPid (PYPD) is a clinical-stage biopharmaceutical company developing locally administered therapeutics based on its proprietary drug delivery platform technology. Targeting areas of unmet medical need, including the prevention of surgical site infections, the company seeks to differentiate itself through a formulation technology that delivers sustained drug release directly to the affected site.
Over the past 1 year, on the higher side
8% below its 1-year high.
Traded about as much as usual. That is 85% of its average volume.
Next earnings report: November 11
10 days to go.
PYPD has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +104.9% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.5%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 17.1%.
Tap to view numbers
It ranks #346 of 597 in the industry
Based on market cap of $109M.
FAQ
What kind of company is PYPD?
PYPD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PYPD?
The market cap of PYPD is approximately $109M, ranking 4,409 within its sector.
What is the 52-week high and low for PYPD?
PYPD has recorded a 52-week high of $5.84 and a low of $3.50.
